Objective: Adjuvant chemotherapy (AC) after curative resection is known to improve the survival of patients with non-small cell lung cancer (NSCLC); however, few studies have reported the correlation between the time ...Objective: Adjuvant chemotherapy (AC) after curative resection is known to improve the survival of patients with non-small cell lung cancer (NSCLC); however, few studies have reported the correlation between the time to initiation of AC (TTAC) and survival in NSCLC patients. Methods: The clinical data of 925 NSCLC patients who received curative resection and post-operative AC at the Cancer Hospital of Chinese Academy of Medical Sciences between 2003 and 2013 were retrospectively analyzed. TTAC was measured from the date of surgery to the initiation of AC. Disease-free survival (DFS) was defined as the duration from surgery to the time of tumor recurrence or last follow-up evaluation. The optimal cut-off value of TTAC was determined by maximally selected log-rank statistics. The DFS curve was estimated using the Kaplan-Meier method, and the Cox proportional hazards regression model was used to identify risk factors independently associated with DFS. Propensity score matching (PSM) was performed for survival analysis using the match data. Results: The optimal discriminating cut-off value of TTAC was set at d 35 after curative resection based on which the patients were assigned into two groups: group A (<= 35 d) and group B (> 35 d). There was no significant difference in the DFS between the two groups (P=0.246), indicating that the TTAC is not an independent prognostic factor for DFS. A further comparison continued to show no significant difference in the DFS among 258 PSM pairs (P=0.283). Conclusions: There was no significant correlation between the TTAC and DFS in NSCLC patients. Studies with larger samples are needed to further verify this conclusion.展开更多
Background: After achieving morphological remission, existence of few number of leukemic cells in the patient’s blood represents the minimal residual disease (MRD) and its monitoring helps in evaluating early treatme...Background: After achieving morphological remission, existence of few number of leukemic cells in the patient’s blood represents the minimal residual disease (MRD) and its monitoring helps in evaluating early treatment response and future relapse. Patients and methods: Eighty seven newly diagnosed (B-ALL) cases were enrolled in the present study in the time period from October 2013 to October 2016. A panel of 4 monoclonal antibodies (CD10FITC, CD19PE, CD34PercP and CD45APC) were defined at diagnosis and after morphological remission for tracing of minimal residual disease (MRD). Results: Eighty seven newly diagnosed B-ALL cases were included in the present study of which 73 (84%) showed positive expression to CD45 in combination with (CD10, CD19 and CD34) at diagnosis, which allow us to use this combination for further assessment of MRD after morphological remission. In our study 65% of patients had negative MRD ( Conclusion: MRD detection by flow cytometry using the combination of CD45 with CD10, CD19 & CD34 is an easy and reliable method. Patients with positive MRD are at higher risk of relapse and have inferior overall survival rates compared to those with MRD-ve. Future studies focusing on treatment intensification for the group of patients with +ve MRD aiming to improve the treatment outcome are warranted.展开更多
目的:三阴性乳腺癌(triple-negative breast cancer,TNBC)预后差,易复发转移,缺乏有效的治疗手段。本文回顾性分析TNBC及基底细胞型的临床病理因素与预后的关系。方法:纳入江苏省肿瘤医院124例TNBC,Fisher法分析临床病理因素之间的相关...目的:三阴性乳腺癌(triple-negative breast cancer,TNBC)预后差,易复发转移,缺乏有效的治疗手段。本文回顾性分析TNBC及基底细胞型的临床病理因素与预后的关系。方法:纳入江苏省肿瘤医院124例TNBC,Fisher法分析临床病理因素之间的相关性,Kaplan-Meier法分析Ki-67/p53与无进展生存期的相关性,COX回归模型分析无进展生存期的预后因素。结果:TNBC肿块大小与腋窝淋巴结转移相关,Ki-67高表达与腋窝淋巴结转移相关,p53阳性与病理分级相关。TNBC及基底细胞型中,Ki-67高增殖与p53阳性患者具有相对较差的无病生存期(P<0.05)。临床分期、腋窝淋巴结转移阳性、Ki-67高增殖与p53阳性是TNBC无病生存的独立预后因素。结论:本文证实Ki-67及p53是TNBC生存预后的预测因子,为TNBC延长生存、改善预后提供依据。展开更多
文摘Objective: Adjuvant chemotherapy (AC) after curative resection is known to improve the survival of patients with non-small cell lung cancer (NSCLC); however, few studies have reported the correlation between the time to initiation of AC (TTAC) and survival in NSCLC patients. Methods: The clinical data of 925 NSCLC patients who received curative resection and post-operative AC at the Cancer Hospital of Chinese Academy of Medical Sciences between 2003 and 2013 were retrospectively analyzed. TTAC was measured from the date of surgery to the initiation of AC. Disease-free survival (DFS) was defined as the duration from surgery to the time of tumor recurrence or last follow-up evaluation. The optimal cut-off value of TTAC was determined by maximally selected log-rank statistics. The DFS curve was estimated using the Kaplan-Meier method, and the Cox proportional hazards regression model was used to identify risk factors independently associated with DFS. Propensity score matching (PSM) was performed for survival analysis using the match data. Results: The optimal discriminating cut-off value of TTAC was set at d 35 after curative resection based on which the patients were assigned into two groups: group A (<= 35 d) and group B (> 35 d). There was no significant difference in the DFS between the two groups (P=0.246), indicating that the TTAC is not an independent prognostic factor for DFS. A further comparison continued to show no significant difference in the DFS among 258 PSM pairs (P=0.283). Conclusions: There was no significant correlation between the TTAC and DFS in NSCLC patients. Studies with larger samples are needed to further verify this conclusion.
文摘Background: After achieving morphological remission, existence of few number of leukemic cells in the patient’s blood represents the minimal residual disease (MRD) and its monitoring helps in evaluating early treatment response and future relapse. Patients and methods: Eighty seven newly diagnosed (B-ALL) cases were enrolled in the present study in the time period from October 2013 to October 2016. A panel of 4 monoclonal antibodies (CD10FITC, CD19PE, CD34PercP and CD45APC) were defined at diagnosis and after morphological remission for tracing of minimal residual disease (MRD). Results: Eighty seven newly diagnosed B-ALL cases were included in the present study of which 73 (84%) showed positive expression to CD45 in combination with (CD10, CD19 and CD34) at diagnosis, which allow us to use this combination for further assessment of MRD after morphological remission. In our study 65% of patients had negative MRD ( Conclusion: MRD detection by flow cytometry using the combination of CD45 with CD10, CD19 & CD34 is an easy and reliable method. Patients with positive MRD are at higher risk of relapse and have inferior overall survival rates compared to those with MRD-ve. Future studies focusing on treatment intensification for the group of patients with +ve MRD aiming to improve the treatment outcome are warranted.
文摘目的探讨经手术治疗的宫颈鳞癌患者治疗前中性粒细胞与淋巴细胞比(neutrophil-tolymphocyte ratio,NLR)及血小板与淋巴细胞比(platelet-to-lymphocyteratio,PLR)与总生存期(overall survival,OS)、无病生存期(disease-free survival,DFS)和各临床病理因素的相关性。方法回顾性分析中山大学附属第一医院于2005年1月1日至2009年12月31日期间初治的并且经过手术治疗的143例宫颈鳞癌患者的临床病理资料,根据统计学方法选取NLR和PLR截断值,将患者根据截断值分组,分析NLR和PLR与患者生存、复发情况的相关性以及与临床病理因素的相关性。结果选取NLR=2.8和PLR=125分别作为截断值,高NLR组5年生存率为30.3%,低NLR组5年生存率为80%,差异有统计学意义(P=0.000)。高NLR组复发率为69.7%,低NLR组复发率为24.5%,差异有统计学意义(P=0.000)。高PLR组5年生存率为53.7%,低PLR组5年生存率为81.6%,差异有统计学意义(P=0.000)。高PLR组复发率为50%,低PLR组复发率为22.4%,差异有统计学意义(P=0.000)。经过单因素和多因素分析,国际妇产科联盟(International Federation of Gynecology and Obstetrics,FIGO)分期、术前化疗、病灶大小、外周血血小板计数(platelet,PLT),NLR值和PLR值是影响宫颈鳞癌患者总生存率和无病生存率的独立危险因素。结论治疗前NLR及PLR均是影响宫颈鳞癌患者总生存时间和无病生存时间的独立危险因素。
文摘目的:三阴性乳腺癌(triple-negative breast cancer,TNBC)预后差,易复发转移,缺乏有效的治疗手段。本文回顾性分析TNBC及基底细胞型的临床病理因素与预后的关系。方法:纳入江苏省肿瘤医院124例TNBC,Fisher法分析临床病理因素之间的相关性,Kaplan-Meier法分析Ki-67/p53与无进展生存期的相关性,COX回归模型分析无进展生存期的预后因素。结果:TNBC肿块大小与腋窝淋巴结转移相关,Ki-67高表达与腋窝淋巴结转移相关,p53阳性与病理分级相关。TNBC及基底细胞型中,Ki-67高增殖与p53阳性患者具有相对较差的无病生存期(P<0.05)。临床分期、腋窝淋巴结转移阳性、Ki-67高增殖与p53阳性是TNBC无病生存的独立预后因素。结论:本文证实Ki-67及p53是TNBC生存预后的预测因子,为TNBC延长生存、改善预后提供依据。
